Dossier
clinical trial diversity
Coverage of clinical trial diversity in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
Novartis acquired Myricx Bio for $1.1 billion to advance its antibody-drug conjugate (ADC) pipeline with a novel NMTi payload. Congressional Republicans passed a bill funding the FDA, including a report urging the agency to implement requirements for diversifying clinical trials.
- STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
GOP lawmakers are urging Trump’s FDA to ensure clinical trials include diverse participants. The Trump administration removed DEI references from HHS websites, but supporters argue clinical trial diversity focuses on patient similarity, not hiring or social initiatives.